Venlafaxine Hydrochloride Capsule, Extended Release
FDA Label NDC 0093-7385

55 label sections · Submitted to the FDA by Teva Pharmaceuticals Usa, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Teva Pharmaceuticals Usa, Inc. for the product Venlafaxine Hydrochloride (NDC 0093-7385). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: suicidal thoughts and behaviors, 1 indications and usage, 2.1 general administration information, 2.2 major depressive disorder, 2.3 generalized anxiety disorder, 2.4 social anxiety disorder (social phobia), 2.5 panic disorder, 2.6 screen for bipolar disorder prior to starting venlafaxine hydrochloride extended-release capsules, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.